[HTML][HTML] Innate and adaptive immune responses in HCV infections
MH Heim, R Thimme - Journal of hepatology, 2014 - Elsevier
Hepatitis C virus has been identified a quarter of a decade ago as a leading cause of
chronic viral hepatitis that can lead to cirrhosis and hepatocellular carcinoma. Only a …
chronic viral hepatitis that can lead to cirrhosis and hepatocellular carcinoma. Only a …
IFN-λ4: the paradoxical new member of the interferon lambda family
TR O'Brien, L Prokunina-Olsson… - Journal of Interferon & …, 2014 - liebertpub.com
Interferons (IFNs) are generally considered antiviral cytokines, yet the newly discovered IFN-
λ4 is linked with the failure to clear hepatitis C virus (HCV) infection either spontaneously or …
λ4 is linked with the failure to clear hepatitis C virus (HCV) infection either spontaneously or …
Цитокины в патогенезе и лечении заболеваний человека
АС Симбирцев - 2018 - elibrary.ru
В монографии приведены сведения по роли цитокинов в регуляции физиологических
процессов, защитных реакций организма и в патогенезе иммунопатологических …
процессов, защитных реакций организма и в патогенезе иммунопатологических …
Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome
EG Meissner, D Wu, A Osinusi, D Bon… - The Journal of …, 2014 - Am Soc Clin Investig
BACKGROUND. Hepatitis C virus (HCV) infects approximately 170 million people worldwide
and may lead to cirrhosis and hepatocellular carcinoma in chronically infected individuals …
and may lead to cirrhosis and hepatocellular carcinoma in chronically infected individuals …
No love lost between viruses and interferons
V Fensterl, S Chattopadhyay… - Annual review of virology, 2015 - annualreviews.org
The interferon system protects mammals against virus infections. There are several types of
interferons, which are characterized by their ability to inhibit virus replication and resultant …
interferons, which are characterized by their ability to inhibit virus replication and resultant …
Reduced IFNλ4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes
E Terczyńska-Dyla, S Bibert, FHT Duong, I Krol… - Nature …, 2014 - nature.com
Hepatitis C virus (HCV) infections are the major cause of chronic liver disease, cirrhosis and
hepatocellular carcinoma worldwide. Both spontaneous and treatment-induced clearance of …
hepatocellular carcinoma worldwide. Both spontaneous and treatment-induced clearance of …
[HTML][HTML] Like a rolling stone? A review on spontaneous clearance of hepatitis C virus infection
P Rzymski, M Brzdęk, K Dobrowolska, B Poniedziałek… - Viruses, 2024 - mdpi.com
Elimination of hepatitis C virus (HCV) without the need for medical intervention, known as
spontaneous clearance (SC), occurs at a significantly lower rate than in the case of hepatitis …
spontaneous clearance (SC), occurs at a significantly lower rate than in the case of hepatitis …
Selection on a Variant Associated with Improved Viral Clearance Drives Local, Adaptive Pseudogenization of Interferon Lambda 4 (IFNL4)
Interferon lambda 4 gene (IFNL4) encodes IFN-λ4, a new member of the IFN-λ family with
antiviral activity. In humans IFNL4 open reading frame is truncated by a polymorphic frame …
antiviral activity. In humans IFNL4 open reading frame is truncated by a polymorphic frame …
[HTML][HTML] Genetics of liver disease: from pathophysiology to clinical practice
TH Karlsen, F Lammert, RJ Thompson - Journal of Hepatology, 2015 - Elsevier
Paralleling the first 30 years of the Journal of Hepatology we have witnessed huge
advances in our understanding of liver disease and physiology. Genetic advances have …
advances in our understanding of liver disease and physiology. Genetic advances have …
Innate and adaptive immune responses in chronic HCV infection
LB Dustin - Current drug targets, 2017 - ingentaconnect.com
Hepatitis C virus (HCV) remains a public health problem of global importance, even in the
era of potent directly-acting antiviral drugs. In this chapter, I discuss immune responses to …
era of potent directly-acting antiviral drugs. In this chapter, I discuss immune responses to …